IP Library Granted Patent US 9,200,268
Granted Patent B2
US 9,200,268 · App. 13/830,372 · Granted Dec 1, 2015

Compounds and methods for purification of serine proteases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,200,268
App. No.
13/830,372
Granted
Dec 1, 2015
Kind
B2
Abstract

Disclosed herein are compounds, compositions, methods and kits for purifying a serine protease and serine proteases purified with the compounds, compositions and methods.

Claims (96)

1. A compound of Formula I:

or a salt thereof,

wherein:

R 1 is —CF 3 , —SO 2 CH 3 , —X-L-R,

R 2 is —OCH 3 , or X-L-R;

R 3 is hydrogen or chloro;

X is O, S, SO 2 , C(O)NH, NHC(O) or NH;

L-R is -L 1 -R,

L 1 -R is

L 2 -R is H,

L 3 -R is

R is NH 2 ;

q is 2, 3, 4, 5, 6 or 7;

r is 1, 2, 3, 4, 5, 6 or 7;

s is 1, 2, 3, 4, 5, 6 or 7;

t is 1, 2, 3, 4, 5, 6 or 7;

n, m, and p are either 0 or 1, with the provisos that

(1) when R 1 is

—CF 3 or —SO 2 CH 3 , and R 2 is —OCH 3 , then one of n, m, and p must be 1, and the others of n, m, and p must be zero; and

(2) when R 1 is other than

—CF 3 or —SO 2 CH 3 , or R 2 is X-L-R, then all of n, m, and p must be zero.

2. The compound of claim 1 , which is of Formula I-A:

wherein the variables are as defined in claim 1 .

3. The compound of claim 1 , which is of Formula I-C:

4. The compound of claim 1 , wherein R 1 is

5. The compound of claim 1 , wherein R 2 is —OCH 3 .

6. The compound of claim 1 , wherein R 2 is X-L-R.

7. The compound of claim 1 , wherein R 3 is hydrogen.

8. The compound of claim 1 , wherein R 3 is chloro.

9. The compound of claim 1 , wherein each X is O.

10. The compound of claim 1 , wherein each X is S or SO 2 .

11. The compound of claim 1 , wherein each X is NH.

12. The compound of claim 1 , wherein L-R is -L 1 -R or

13. The compound of claim 1 , wherein L 1 -R is

14. The compound of claim 1 , wherein L-R is selected from the group consisting of:

—X-L-R is selected from the group consisting of

15. The compound of claim 1 , wherein each of q, r, s, and t is at least 3.

16. A compound selected from:

or a salt thereof.

17. An affinity solid support of Formula II:

or a salt thereof,

wherein:

R 21 is —CF 3 , —SO 2 CH 3 , —X-L-Y—Z,

R 22 is —OCH 3 , or X-L-Y—Z;

R 23 is hydrogen or chloro;

X is O, S, SO 2 , C(O)NH, NHC(O) or NH;

L-Y—Z is -L 1 -Y—Z,

L 1 -Y—Z is

L 2 -Y—Z is

L 3 -Y—Z is

Y—Z is

Z is a solid support;

q is 2, 3, 4, 5, 6 or 7;

r is 1, 2, 3, 4, 5, 6 or 7;

s is 1, 2, 3, 4, 5, 6 or 7;

t is 1, 2, 3, 4, 5, 6 or 7;

v is 1, 2, 3, 4, 5, 6 or 7;

u is 1, 2, 3, 4, 5, 6 or 7;

w is 1, 2 or 3;

n, m, and p are either 0 or 1, with the provisos that

(1) when R 21 is

—CF 3 or —SO 2 CH 3 , and R 22 is —OCH 3 , then one of n, m, and p must be 1, and the others of n, m, and p must be zero; and

(2) when R 21 is other than

—CF 3 or —SO 2 CH 3 , or R 22 is X-L-Y—Z, then all of n, m, and p must be zero.

18. The affinity solid support of claim 17 of Formula II-A:

wherein the variables are as defined in claim 17 .

19. The affinity solid support of claim 17 of Formula II-B:

wherein the variables are as defined in claim 17 .

20. The affinity solid support of claim 17 of Formula II-D:

21. The affinity solid support of claim 17 , wherein R 21 is

22. The affinity solid support of claim 17 , wherein R 22 is —OCH 3 .

23. The affinity solid support of claim 17 , wherein R 22 is X-L-Y—Z.

24. The affinity solid support of claim 17 , wherein R 23 is hydrogen.

25. The affinity solid support of claim 17 , wherein R 23 is chloro.

26. The affinity solid support of claim 17 , wherein each X is O.

27. The affinity solid support of claim 17 , wherein each X is S or SO 2 .

28. The affinity solid support of claim 17 , wherein each X is NH.

29. The affinity solid support of claim 17 , wherein L-Y—Z is -L 1 -Y—Z or

30. The affinity solid support of claim 17 , wherein L-Y—Z is selected from the group consisting of

31. The affinity solid support of claim 17 , wherein L 1 -Y—Z is selected from the group consisting of

32. The affinity solid support of claim 17 , wherein each of q, r, s, and t is at least 3.

33. The affinity solid support of claim 17 , wherein —X-L-Y—Z is selected from the group consisting of

34. The affinity solid support of claim 17 which is

or a salt thereof.

35. The affinity solid support of claim 17 , wherein Z is a cross-linked agarose resin.

36. A method for purifying a serine protease comprising

(1) adding a first composition comprising the serine protease to an affinity solid support of claim 17 or a salt thereof to form a second composition comprising the serine protease and the affinity solid support of claim 17 , and

(2) eluting the serine protease from the second composition with an elution buffer comprising a competitive agent.

37. The method of claim 36 , wherein the competitive agent is arginine and/or benzamidine, or a salt thereof.

38. The method of claim 36 , wherein the serine protease is a fXa derivative.

39. The method of claim 36 , wherein the serine protease is a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 2, or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1 or 2.

40. A kit for purifying a serine protease comprising

(1) an affinity solid support of claim 17 , and

(2) an elution buffer comprising a competitive agent.

41. A kit for purifying a serine protease comprising a compound of claim 2 and a resin of the Formula NC—O—Z or

wherein Z is a solid support.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2022
From: ALEXION PHARMACEUTICALS, INC.
To: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
Reel/Frame 060799/0729 →
CHANGE OF NAME Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054920/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054921/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054922/0857 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
SECURITY INTEREST Recorded Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2013
From: PANDEY, ANJALI; ROSE, JACK W.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 030514/0451 →